| Literature DB >> 32359943 |
Xiao-Shan Wei1, Xiao-Rong Wang1, Jian-Chu Zhang1, Wei-Bing Yang1, Wan-Li Ma1, Bo-Han Yang1, Nan-Chuan Jiang2, Zhan-Cheng Gao3, Huan-Zhong Shi4, Qiong Zhou5.
Abstract
BACKGROUND: The current outbreak of coronavirus disease 2019 (COVID-19) caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, Hubei, China, spreads across national and international borders.Entities:
Keywords: COVID-19; Health care workers; SARS-CoV-2
Mesh:
Year: 2020 PMID: 32359943 PMCID: PMC7185000 DOI: 10.1016/j.jmii.2020.04.013
Source DB: PubMed Journal: J Microbiol Immunol Infect ISSN: 1684-1182 Impact factor: 4.399
Fig. 1Results of SARS-CoV-2 detection in health care workers during hospitalization.
Demography and Symptoms in Health Care Workers with COVID-19 at admission.
| Sex | Patient No. | Summary | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | ||
| Male | Male | Female | Female | Female | Female | Female | Female | Female | Female | Female | Male | Male | Female | ||
| Age (yr) | 32 | 34 | 34 | 32 | 41 | 41 | 35 | 36 | 35 | 43 | 51 | 33 | 27 | 36 | 36±6 |
| Occupation | Nurse | Nurse | Nurse | Nurse | Nurse | Nurse | Nurse | Nurse | Nurse | Nurse | Nurse | Doctor | Doctor | Nurse | – |
| Smoking history | Never | Never | Never | Never | Never | Never | Never | Never | Never | Never | Never | Never | Never | Never | – |
| Underlying disease | – | – | – | – | – | – | – | – | – | – | – | – | + | – | 1+ |
| Symptoms | |||||||||||||||
| Myalgia or fatigue | + | + | + | + | + | + | + | + | + | + | + | + | + | + | 14+ |
| Fever | + | – | + | + | + | + | + | + | + | + | – | + | + | + | 12+ |
| Headache | – | + | – | + | + | + | + | + | – | + | + | – | – | – | 8+ |
| Pharyngalgia | + | + | + | + | – | – | + | – | – | + | + | – | – | – | 7+ |
| Cough | + | + | + | + | – | + | – | + | + | + | + | + | – | – | 10+ |
| Sputum | – | + | + | + | – | + | – | – | – | – | + | – | – | – | 5+ |
| Dyspnea | – | – | – | – | + | + | – | – | – | – | – | – | – | – | 2+ |
| Diarrhea | + | + | + | + | + | + | – | + | + | – | + | – | – | – | 9+ |
| Vomiting | – | – | – | – | + | + | – | – | – | – | – | – | – | – | 2+ |
Means ±SD.
Fig. 2Time of Onset of Symptoms in the Clinical Course. The distribution and lasting days of myalgia or fatigue (A), fever (B), dry cough (C), and diarrhea (D), headache (E), and pharyngalgia (F) in the infected HCWs with COVID-19 pneumonia.
Laboratory findings in Health Care Workers with COVID-19 during hospitalization (N = 14).
| Variable | Day 1 | Day 3 | Day 5 | Day 10 |
|---|---|---|---|---|
| White blood cell counts, × 109/L | 3.4 ± 1.3 | 4.6 ± 2.8 | 5.3 ± 1.6 | 4.3 ± 1.3 |
| <3.5 -- no. (%) | 11 (79) | 6 (43) | 1 (7) | 3 (21) |
| 3.5–9.5 -- no. (%) | 3 (21) | 7 (50) | 13 (93) | 11 (79) |
| >9.5 -- no. (%) | 0 | 1 (7) | 0 | 0 |
| Neutrophils, × 109/L | 1.8 ± 0.9 | 2.6 ± 1.8 | 3.8 ± 1.6 | 2.5 ± 0.8 |
| Lymphocytes, × 109/L | 1.1 ± 0.4 | 1.3 ± 0.5 | 1.3 ± 0.4 | 1.5 ± 0.4 |
| <1.1 -- no. (%) | 6 (43) | 5 (36) | 5 (36) | 3 (21) |
| 1.1–3.2 -- no. (%) | 8 (57) | 9 (64) | 9 (64) | 11 (79) |
| Platelets, × 109/L | 174 ± 63 | 180 ± 51 | 188 ± 60 | 242 ± 50 |
| Haemoglobin, g/L | 126.0 ± 14.2 | 125.1 ± 16.4 | 123.9 ± 16.7 | 119.7 ± 15.9 |
| Alanine aminotransferase, U/L | 17.1 ± 7.0 | 18.3 ± 6.1 | 17.6 ± 6.9 | 17.7 ± 7.2 |
| Aspartate aminotransferase, U/L | 22.4 ± 4.2 | 26.6 ± 5.4 | 27.9 ± 6.2 | 24.5 ± 4.9 |
| Albumin, g/L | 41.3 ± 2.9 | 44.4 ± 3.5 | 49.1 ± 4.7 | 45.2 ± 4.1 |
| Total bilirubin, μmol/L | 7.5 ± 1.6 | 7.7 ± 1.4 | 7.5 ± 1.9 | 8.1 ± 1.8 |
| Direct bilirubin, μmol/L | 2.7 ± 0.9 | 3.1 ± 0.7 | 2.8 ± 1.1 | 2.8 ± 0.9 |
| Creatinine, μmol/L | 65.2 ± 13.1 | 64.8 ± 19.4 | 71.1 ± 15.3 | 70.9 ± 14.1 |
| Blood urea nitrogen, mmol/L | 3.3 ± 1.1 | 3.0 ± 0.9 | 3.9 ± 1.3 | 3.4 ± 1.2 |
| Creatine kinase, U/L | 63.3 ± 22.7 | 79.9 ± 31.8 | 73.8 ± 24.6 | 70.9 ± 29.7 |
| Lactic dehydrogenase, U/L | 203.9 ± 51.0 | 231.9 ± 48.9 | 208.4 ± 42.8 | 187.8 ± 45.9 |
| Prothrombin time, s | 13.9 ± 2.9 | 14.0 ± 2.1 | 13.1 ± 2.2 | 13.5 ± 2.6 |
| Activated partial thromboplastin time, s | 40.2 ± 4.2 | 38.3 ± 4.1 | 36.1 ± 3.2 | 39.2 ± 4.9 |
| D-Dimer, mg/L | 0.3 ± 0.2 | 0.4 ± 0.2 | 0.4 ± 0.1 | 0.3 ± 0.3 |
| C-reaction protein, mg/L -- no. (%) | ||||
| <8.0 | 8 (57.1) | 6 (42.9) | 7 (50) | 9 (64.3) |
| ≥8.0 | 6 (42.9) | 8 (57.1) | 7 (50) | 5 (35.7) |
| Procalcitonin, μg/L -- no. (%) | ||||
| <0.5 | 14 (100) | 12 (86) | 14 (100) | 14 (100) |
| Erythrocyte sedimentation rate, mm/h | 13.2 ± 9.4 | 21.7 ± 8.5 | 17.2 ± 7.3 | 10.9 ± 5.2 |
P < 0.05 compared with Day 1.
Fig. 3Pulmonary CTs of two suspected infected HCWs with COVID-19 pneumonia. Transverse chest CT images from Patient 13 (A) showed patchy consolidation in the left lower lobe of lung, (B) the density of consolidation decreases, showing as ground-glass opacity, (C) lesion completely resolved; Transverse chest CT images from Patient 14 (D) showed patchy shadows and ground glass density in the middle lobe of the right lung, (E) the lesion was reduced in the middle lobe of the right lung, and newly small patchy shadows appeared in the left lower lobe of the lung, (F) the lesions in the middle lobe of the right lung and the lower lobe of the left lung were almost resloved, showing as ground-glass opacity.